About Rab GDP dissociation inhibitor beta
Rab GDP dissociation inhibitor beta (GDI2) is a protein
from Homo sapiens identified by UniProt accession
P50395, 445 residues long.
MolForge cross-references it against 0 known binders and
158 disease associations.
Target properties
| Protein name | Rab GDP dissociation inhibitor beta |
| UniProt accession | P50395 |
| Gene | GDI2 |
| Organism | Homo sapiens |
| Length | 445 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (158)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- blood protein measurement · score 0.34
- cutaneous melanoma · score 0.27
- nevus count · score 0.27
- monocyte count · score 0.22
- drug use measurement · score 0.19
- body height · score 0.16
- age at menopause · score 0.16
- monocyte percentage of leukocytes · score 0.14
- systemic lupus erythematosus · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P50395-F1 | alphafold | PREDICTED | 93.79 | — |
Amino-acid sequence (445 residues)
MNEEYDVIVL GTGLTECILS GIMSVNGKKV LHMDRNPYYG GESASITPLE DLYKRFKIPG SPPESMGRGR DWNVDLIPKF LMANGQLVKM LLYTEVTRYL DFKVTEGSFV YKGGKIYKVP STEAEALASS LMGLFEKRRF RKFLVYVANF DEKDPRTFEG IDPKKTTMRD VYKKFDLGQD VIDFTGHALA LYRTDDYLDQ PCYETINRIK LYSESLARYG KSPYLYPLYG LGELPQGFAR LSAIYGGTYM LNKPIEEIIV QNGKVIGVKS EGEIARCKQL ICDPSYVKDR VEKVGQVIRV ICILSHPIKN TNDANSCQII IPQNQVNRKS DIYVCMISFA HNVAAQGKYI AIVSTTVETK EPEKEIRPAL ELLEPIEQKF VSISDLLVPK DLGTESQIFI SRTYDATTHF ETTCDDIKNI YKRMTGSEFD FEEMKRKKND IYGED
Explore Rab GDP dissociation inhibitor beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets